TIS 0.00% 0.0¢ tissue therapies limited

consultantcy fees

  1. 793 Posts.
    lightbulb Created with Sketch. 4
    Hello all.

    I am certainly no expert in these matters but that arrangement sounds like a ride on the gravy train to me. As someone noted, where is the commercial? If we had Vitrogo on the market it might seem less confronting but that arrangement looks like an expensive one to me?

    Perhaps I am wrong and that is normal for this industry, any opinions?

    Although I am not sure on the above I am sure of one thing, the CEO is probably sweating a little more now knowing that Morf is about to call. He cannot put the call off forever somif he is temporarily busy keep trying Morf. Great to see people with real industry credence putting some hard questions to those who get paid the big bucks. I look forward to hearing what the companies strategy is moving forward and I am sure many others feel the same. The comms in this company have not been the best IMO.

    Go Morf you good thing!

    Surfrat
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.